Featured Content
Both immune suppressive therapy (IST) and bone marrow transplant (BMT) are potentially curative for severe aplastic anemia (SAA). Currently BMT is the therapy of choice for young patients who have a matched sibling or other family donor; ...
A clinical trial underway at Roswell Park aims to expand treatment options patients with advanced refractory sarcoma with a novel approach to immunotherapy.
Pediatric Multicenter Study Shows Targeted Therapy for High-Risk Hodgkin Lymphoma Reduces Relapse
BUFFALO, N.Y. and ATLANTA, GA. — A targeted therapy for children with high-risk Hodgkin lymphoma (HL) was shown to significantly reduce relapse rates when tested in a large multicenter clinical trial conducted by the Children’s Oncology ...
From ASCO 2022: Brentuximab Vedotin and Chemotherapy an Effective Treatment for Hodgkin Lymphoma
Children’s Oncology Group study shows benefit for children and adolescents with high-risk HL treated with the combination
A multidisciplinary research team led by Song Yao, PhD, Professor of Oncology in the Department of Cancer Prevention and Control at Roswell Park Comprehensive Cancer Center and Kara Kelly, MD, Chair of the Roswell Park Oishei Children’s ...
Checkmate 744: Subgroup Analyses of an International Trial for Relapsed Pediatric Hodgkin Lymphoma
Kara Kelly, MD, Chair of the Department of Pediatric Oncology at Roswell Park Comprehensive Cancer Center, presents a subgroup analyses of an international trial for relapsed pediatric Hodgkin Lymphoma.
This site is intended for healthcare professionals